Aurobindo receives USFDA approval for Ciprofloxacin

New Delhi, June 5 (UNI) Aurobindo Pharma Ltd today said it has received USFDA approval for its Ciprofloxacin tablets in strengths 250, 500 and 750 mg.

The drug is considered a yardstick with which the other quinolones efficacies are measured against. Ciprofloxacin is a broad-spectrum antibiotic that is active against both gram-positive and gram-negative bacteria.

It is used in lower respiratory infections (pneumonias), urinary tract infections, STDs, septicemias, Legionellosis and in some atypicals.

The drug belongs to the class of floroquinolones and is the generic international name for the synthetic microbicide manufactured and sold by Bayer Pharmaceutical under the brand names Cipro, Ciproxin and Ciprobay.

Ciprofloxacin enjoys a market of over 230 million dollars in the US.

''The company has informed that, it regrets its earlier announcement of cefpodoxime proxetil approval which was displayed by the FDA. However, this product is still waiting for the official approval,'' the company said in a statement.

UNI